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Abstract: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung 
disease characterized by airflow limitation that is not fully reversible. In a significant proportion of 
patients with COPD, reduced lung elastic recoil combined with expiratory flow limitation leads 
to lung hyperinflation during the course of the disease. Development of hyperinflation during the 
course of COPD is insidious. Dynamic hyperinflation is highly prevalent in the advanced stages 
of COPD, and new evidence suggests that it also occurs in many patients with mild disease, 
independently of the presence of resting hyperinflation. Hyperinflation is clinically relevant for 
patients with COPD mainly because it contributes to dyspnea, exercise intolerance, skeletal 
muscle limitations, morbidity, and reduced physical activity levels associated with the disease. 
Various pharmacological and nonpharmacological interventions have been shown to reduce 
hyperinflation and delay the onset of ventilatory limitation in patients with COPD. The aim of 
this review is to address the more recent literature regarding the pathogenesis, assessment, and 
management of both static and dynamic lung hyperinflation in patients with COPD. We also 
address the influence of biological sex and obesity and new developments in our understand-
ing of hyperinflation in patients with mild COPD and its evolution during progression of the 
disease.
Keywords: chronic obstructive pulmonary disease, hyperinflation, expiratory flow limitation, 
operational lung volumes
Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung 
disease characterized by airflow limitation that is not fully reversible.1 COPD is 
a leading cause of mortality and morbidity worldwide, even if it remains largely 
underdiagnosed.2,3 Currently, the prevalence of the disease is estimated to be 
around 10% in the population aged .40 years4 and could reach around 20%–30%5,6 
when including milder patients (Global initiative for chronic Obstructive Lung 
Disease [GOLD] stage 1).1
In a significant proportion of patients with COPD, reduced lung elastic recoil 
combined with expiratory flow limitation eventually leads to lung hyperinflation dur-
ing the course of the disease.7 In patients with COPD, the lung can be hyperinflated 
at rest (static hyperinflation) and/or during exercise (dynamic hyperinflation) when 
ventilatory requirements are increased and expiratory time is shortened. Hyperinflation 
is clinically relevant for patients with COPD mainly because it contributes to the 
 dyspnea8 and morbidity associated with the disease.9 In fact, although measurement 
of expiratory flows is a prerequisite for the diagnosis and staging of COPD, the effects 
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of the disease on static and dynamic lung volumes correlate 
better with patient symptoms and impairment in functional 
capacity than spirometric indices of the disease.10 Moreover, 
dynamic lung hyperinflation is related to reduced daily physi-
cal activity in COPD,11 which is an important component of 
quality of life.12
Despite the difficulties in establishing a cause-effect 
relationship, exercise intolerance and lung hyperinflation are 
closely interrelated in COPD.13,14 While exercise intolerance 
in patients with COPD is complex and multifactorial,15–17 
dynamic hyperinflation remains a major contributor to exercise 
limitation that is consistently observed in this disease.18 Dur-
ing exercise, hyperinflation may impede cardiac19,20 and respi-
ratory muscle function and increase the work of breathing.21 
Finally, this phenomenon can also occur in patients with mild 
disease,22–24 a category of individuals likely representing a 
great portion of patients diagnosed with COPD.5
This review addresses the more recent literature regard-
ing the pathogenesis of both static and dynamic lung 
hyperinflation. The pathophysiology and physiological con-
sequences of lung hyperinflation are summarized, as well as 
management, pharmacological treatment, and the impact of 
pulmonary rehabilitation on hyperinflation. We also address 
the influence of biological sex and obesity and new develop-
ments in our understanding of hyperinflation in mild COPD 
patients and its evolution during progression of the disease. 
The review is based on literature available on the PubMed 
database, irrespective of the year of publication.
Pathophysiology of hyperinflation
Lung volumes can be divided into several compartments 
defined by the normal cycle of tidal breathing and the maxi-
mum capacity to inhale and exhale (Figure 1A). In health, 
during relaxed tidal breathing, the lungs tend to return to a 
basal level of inflation, which is termed functional residual 
capacity (FRC) or end-expiratory lung volume (EELV). 
During the hyperpnea of exercise, both tidal volume (V
T
) 
and respiratory rate increase to meet the increased ventila-
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Figure 1 Lung volumes and capacities at rest and during exercise.
Notes: Lung volumes and capacities in a healthy elderly control (A and C) and in an aged-matched COPD patient (B and D). Gray parts represents lung volumes during exercise.
Abbreviations: COPD, chronic obstructive pulmonary disease; eeLv, end-expiratory lung volume; eILv, end-inspiratory lung volume; eRv, expiratory reserve volume; FRC, 
functional residual capacity; FvC, forced vital capacity; IC, inspiratory capacity; IRv, inspiratory reserve volume; Rv, residual volume; vT, tidal volume.
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tory requirements. Therefore, maintenance of stable lung 
volumes requires that expiratory muscles must be recruited 
to elevate pleural and alveolar pressure, increase expiratory 
flow, and force the increased V
T
 to be completely exhaled 
before the next inhalation.25
Hyperinflation, defined as an increased volume of air 
remaining in the lung at the end of spontaneous expira-
tions, is present when resting FRC or EELV is increased 
above normal.26 Two types of hyperinflation can be distin-
guished, ie, static and dynamic hyperinflation. A significant 
proportion of patients with COPD have some degree of 
lung hyperinflation, which often remains undetected in 
the absence of detailed physiological analysis (see sec-
tion on assessment). Both static and dynamic effects of 
breathing contribute differently to lung hyperinflation 
in COPD.
Static and dynamic hyperinflation
Static hyperinflation
Under normal physiological conditions, for a given change 
in pleural pressure generated by the respiratory muscles, the 
attainable end-inspiratory lung volume (EILV) and EELV 
are determined by the passive pressure–volume relationship 
of the respiratory system (Figure 2).26,27 In healthy subjects, 
elastic recoil pressure of the respiratory system decreases 
progressively during exhalation, reaching zero at FRC or 
EELV and the elastic work of breathing is minimized by 
maintaining V
T
 within 20%–80% of the vital capacity range. 
With advancing age, damage to the connective tissue of 
the lung occurs, resulting in a reduction of the lung elastic 
recoil pressure.28 The equilibrium point (FRC or EELV) 
therefore occurs at a higher lung volume than in younger 
subjects, with a consequence of an increased volume of air 
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Figure 2 Pressure–volume relationships of the total respiratory system.
Notes: Pressure–volume relationships of the total respiratory system in healthy subjects (A) and in COPD (B). Tidal pressure–volume curves during rest (black) and 
exercise (gray) are shown. In COPD, the ability to further expand tidal volume is reduced. In contrast with health, the combined recoil pressure of the lungs and chest wall 
in hyperinflated patients with COPD is inwardly directed during both rest and exercise. Reproduced with permission of the European Respiratory Society. Eur Respir Rev 
December 2006 15:61–67; doi:10.1183/09059180.00010002.26 Copyright © remains with european Respiratory Society.
Abbreviations: COPD, chronic obstructive pulmonary disease; eeLv, end-expiratory lung volume; IRv, inspiratory reserve volume; P, pressure; Rv, residual volume; TLC, total 
lung capacity; v, volume. 
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remaining in the lung at the end of spontaneous expirations. 
This is referred to as static hyperinflation, which exists at 
rest.28 In COPD with emphysema, the lung recoil pressure is 
further reduced by a reduced elastic load related to smoking 
or α1-antitrypsin deficiency.29 Therefore, the elastic recoil 
pressure of the respiratory system falls to zero at a larger 
FRC or EELV, resulting in more static hyperinflation.
Dynamic hyperinflation
Dynamic lung hyperinflation refers to the temporary increase 
in EELV above the resting value during periods of increased 
ventilatory needs (eg, exercise). It is dependent on operational 
lung volumes and expiratory time, and is thus a key mecha-
nistic consequence of expiratory flow limitation.14
During exercise, respiratory rate increases and V
T
 expands 
to accommodate increased respiratory demands. The hyper-
pnea induces phasic activity of expiratory muscles in both 
healthy individuals and in those with COPD.30,31 In healthy 
individuals, the increased expiratory effort progressively 
decreases EELV and expiratory airflows are sufficient to allow 
complete exhalation of the inhaled V
T
 before the next inhala-
tion, even when breathing approaches maximal ventilation. 
In contrast, the combined effects of decreased lung elastic 
recoil pressure and increased airways resistance in patients 
with COPD results in an increased mechanical time con-
stant for lung emptying in many alveolar units. Thus, as the 
respiratory rate and expiratory flow increases, the expiratory 
time available for exhalation can become insufficient and 
complete exhalation of V
T
 to the relaxation volume becomes 
increasingly compromised, and EELV usually increases with 
hyperpnea.32 In addition, similar to healthy subjects, patients 
with COPD recruit expiratory muscles to increase their pleu-
ral and alveolar pressures, in an effort to increase expiratory 
flow. However, in these patients, the airways typically collapse 
when the pleural pressure becomes positive, thereby prevent-
ing increased expiratory flow.33 As a result, exhalation may 
not be completed prior to the onset of the next breath, caus-
ing an increase in operational lung volumes and progressive 
air retention called “air trapping”.13,26,34 This is referred to 
as dynamic hyperinflation, which can occur independently 
of static hyperinflation. Usually observed during exercise, 
the onset of dynamic hyperinflation will also occur at lower 
minute ventilations as disease severity limiting exhalation 
worsens, and may even occur during quiet breathing in severe 
patients or during an acute exacerbation.14,35
Natural history of hyperinflation
Development of hyperinflation during the course of COPD 
is insidious. In early COPD, the forced expiratory volume 
in one second (FEV
1
) may not be the optimal indicator of 
small airways obstruction.36 In fact, considering the extent 
of small airway inflammation reported in patients with mild 
COPD,37 it is conceivable that substantial structural dam-
ages could have taken place before marked expiratory flow 
limitation is objectively measured via FEV
1
.38 Early changes 
observed in pulmonary function of heavy smokers without 
COPD likely imply increased total lung capacity (TLC) and 
residual volume because of the loss of elastic recoil.39 These 
early changes reflecting lung hyperinflation are observed 
without any apparent reduction in FEV
1
.39 In mild COPD, 
measures of TLC, FRC, and residual volume were found to 
be significantly above predicted values while vital capacity 
and inspiratory capacity (IC) were preserved.40 Throughout 
the continuum of hyperinflation from mild to more severe 
COPD, vital capacity and IC decrease linearly with the pro-
gression of airflow obstruction (FEV
1
 decline). On the other 
hand, the progressive increase in TLC, FRC, and residual 
volume appears to be exponential with the worsening airflow 
limitation during the course of COPD.40
During exercise, some studies report that dynamic hyper-
inflation is already present in patients with mild disease 
(GOLD stage 1), even when resting hyperinflation is slightly 
present22,23 or absent.24,41–43 Even if patients with mild COPD 
usually have preserved resting IC, they still exhibit dynamic 
hyperinflation and abnormal ventilatory mechanics during 
exercise when compared with healthy controls.22,44 At peak 
exercise, notwithstanding the severity of the disease, patients 
seem to show a consistent fall of approximately 20% of their 
resting IC at peak exercise.22–24,45–48
In patients with moderate-to-severe COPD, the level of 
dynamic hyperinflation is poorly related to FEV
1
.49 How-
ever, when comparing two patients with similar FEV
1
, the 
one presenting with a reduced diffusion capacity, more 
severe small airway obstruction, and a higher ventilatory 
response to exercise will tend to develop more dynamic 
hyperinflation early during exercise.13 Moderate levels of 
dynamic hyperinflation can even be observed in healthy 
elderly individuals aged .70 years without any pulmonary 
disease following normal aging of the lung parenchyma.50–52 
Likewise, the ventilatory response during exercise of a 
healthy elderly subject could be similar to that of a patient 
with GOLD stage 1 COPD.53
Physiological and sensory 
consequence of lung hyperinflation
Dyspnea
The interrelation between hyperinflation and dyspnea 
has been evaluated indirectly using regression analysis. 
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O’Donnell and Webb54 evaluated 23 patients with severe 
COPD and found that the change in EILV from baseline 
was the strongest predictor of the change in Borg dysp-
nea ratings (r=0.63, P,0.001). In this study, EELV and 
V
T
 (both components of EILV) combined with breathing 
frequency accounted for 61% of the variance in dyspnea 
intensity. A subsequent study in a larger cohort of COPD 
patients (n=105) demonstrated that the V
T
/IC ratio, an index 
of EILV and V
T
 constraint, was the strongest predictor 
of exertional dyspnea based on multiple linear regression 
analysis.13  Moreover, interventions that deflate the lungs (ie, 
reduce EILV and EELV) and delay the onset of critical V
T
 
constraints consistently reduce dyspnea intensity in patients 
with COPD during exercise.45,46,55,56
Although dynamic hyperinflation is a cardinal feature of 
COPD with important physiological consequences, a small 
proportion of patients (∼15%–20%) do not dynamically 
hyperinflate during exercise even though they still experi-
ence intolerable dyspnea.13,42,57 Guenette et al42 recently 
evaluated the effects of dynamic hyperinflation on dyspnea 
by comparing a group of well characterized COPD patients 
who did not acutely increase their EELV during exercise 
(nonhyperinflators, n=65) with those that did increase their 
EELV (hyperinflators, n=65). Despite being well matched 
for age, sex, body mass index, and baseline airflow obstruc-
tion, the authors were not able to show that the hyperinfla-
tors experienced more dyspnea than the nonhyperinflators. 
The authors concluded that perhaps the regulation of EILV 
provides a better index of critical constraints to ventilation 
(and therefore dyspnea) during exercise than the behavior 
of dynamic EELV per se. This finding does not necessar-
ily diminish the physiological and sensory significance of 
dynamic hyperinflation, but rather shows that some indi-
viduals with airflow obstruction can still experience similar 
critical V
T
 constraints (and thus similar dyspnea ratings), 
regardless of how they regulate EELV.
Respiratory and limb muscle function
Respiratory muscles
Static lung hyperinflation alters the geometry of the thorax 
and shortens the diaphragm,58 thereby placing the diaphragm 
in a suboptimal contractile position to generate pressure. 
This mechanical disadvantage reduces the force-generating 
capacity of the inspiratory muscles and is likely to become fur-
ther exaggerated in patients who dynamically hyperinflate.59 
Indeed, the ability of the respiratory muscles to generate 
pressure decreases at high lung volumes in humans.58,60 These 
functionally weakened respiratory muscles coupled with the 
increased elastic and threshold loading of the inspiratory 
muscles61 results in a substantial increase in the work and 
oxygen cost of breathing.21,62
Despite the known deleterious effects of static and 
dynamic hyperinflation on respiratory muscle function, 
some have postulated that respiratory muscle strength and 
function may actually be preserved in some patients with 
COPD.58,63,64 Chronic exposure to lung hyperinflation may 
result in physiological adaptations to preserve inspiratory 
muscle strength and perhaps obviate the development of 
diaphragmatic fatigue.65 Some of the documented adaptations 
include: an increase in the relative fraction of fatigue-resistant 
slow-twitch (type I) muscle fibers66 that can occur even in 
mild-to-moderate COPD;67 a reduction in sarcomere length 
which permits an increase in pressure production at higher 
lung volumes;68 increased mitochondrial density;68 and/or an 
improvement in mitochondrial respiratory chain capacity.69
Limb muscles
A direct link between dynamic hyperinflation and peripheral 
muscle function has not been fully established. Studies in 
healthy subjects suggest that high levels of respiratory muscle 
work may result in a sympathetically mediated metaboreflex 
which causes redistribution of blood flow from the locomotor 
muscles to the respiratory muscles.70–72 A reduction in loco-
motor muscle blood flow could result in an accelerated rate 
of development of limb muscle fatigue during exercise. This 
contention is supported by studies that show reduced limb 
muscle fatigue and corresponding improvements in perceived 
leg discomfort when the work of breathing is mechanically 
unloaded during exercise in healthy humans73 and in patients 
with COPD.74 In theory, dynamic hyperinflation and the 
associated increase in work and oxygen cost of breathing may 
compromise blood flow to the periphery, leading to compro-
mised oxygen delivery and therefore causing increased leg 
fatigue. Indeed, studies that have unloaded the respiratory 
muscles of hyperinflated patients with bronchodilators or 
heliox resulted in an improvement in indices of limb muscle 
fractional oxygen extraction.75,76 For example, Louvaris et al77 
recently demonstrated that improving operating lung volumes 
in hyperinflated COPD patients with heliox enhanced oxygen 
delivery to the quadriceps muscles during exercise by increas-
ing arterial oxygen content and blood flow to the quadriceps 
muscles. The authors speculated that this was likely due to 
blood flow redistribution from the respiratory muscles since 
cardiac output was similar between heliox and room air.
Cardiac function
Lung hyperinflation has been shown to adversely affect 
cardiovascular function in patients with COPD. Lung 
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 hyperinflation reduces right ventricular preload and venous 
return at rest and during exercise.78–81 Left ventricular 
afterload may also increase due to the high intrathoracic 
pressure swings needed to overcome the high elastic and 
resistive loads encountered by patients with COPD during 
exercise.80 In addition, right ventricular afterload increases 
during exercise because there is an increase in pulmonary 
vascular resistance resulting from patients breathing at a high 
EILV.82,83 There is also indirect evidence to suggest that lung 
hyperinflation is associated with pulmonary hypertension. 
A number of mechanisms have been proposed to explain 
this association as recently described,84 including increased 
intrathoracic pressures, cardiovascular effects, increased 
lung volume, altered gas exchange, pulmonary vascular 
remodeling, and endothelial dysfunction. Collectively, these 
cardiovascular consequences of lung hyperinflation likely 
contribute, in highly variable combinations, to the reduced 
cardiac performance observed in some COPD patients during 
exercise.20,85 However, it should be acknowledged that not all 
studies have been able to demonstrate a direct link between 
dynamic hyperinflation and cardiac performance during exer-
cise. For example, Stark-Leyva et al86 found that voluntary 
hyperinflation in healthy subjects did not adversely affect 
cardiac output during exercise. It remains to be determined 
if these findings in a healthy model can be extrapolated to 
patients with both static and dynamic hyperinflation, such 
as those with COPD.
exercise tolerance
The mechanisms of exercise intolerance in COPD are 
complex and multifactorial and have been the subject of 
rigorous scientific debate.16–18 Potential mechanisms include 
abnormal ventilatory mechanics, limb muscle dysfunction, 
and impaired cardiac function, among other factors.87 All 
of these mechanisms are related, at least in part, to lung 
hyperinflation as previously described. Thus, it is difficult 
to directly demonstrate a cause–effect relationship between 
hyperinflation and exercise performance because interven-
tions that reduce hyperinflation may also improve any one 
or a combination of these contributory factors to varying 
degrees. Nevertheless, correlative evidence indicates that 
there is a link between exercise performance and indices of 
lung hyperinflation. For example, peak V
T
 relative to pre-
dicted vital capacity was found to be the best predictor of 
peak aerobic capacity (r=0.68, P,0.0005) in 105 patients 
with COPD.13 Work from other groups supports these results 
by showing a significant correlation between resting IC 
and peak work rate and peak oxygen uptake, particularly 
in patients with demonstrable expiratory flow limitation at 
rest.88 The notion that lung hyperinflation is inversely related 
to exercise tolerance is also supported, albeit indirectly, by 
studies showing statistically significant correlations between 
improvements in resting and exercise IC and improvements 
in peak oxygen uptake and cycle endurance time following 
different interventions.46,56,89,90
Influence of comorbidities  
and sex on hyperinflation
Obesity
Obesity is an abnormal or excessive fat accumulation that 
may impair health.91 Added weight on the thorax and abdo-
men (and also the neck), can significantly affect static and 
dynamic lung volumes along with respiratory mechanics,92–112 
usually in a dose-response fashion. While several studies have 
addressed this issue, significant variability has been observed 
when evaluating the effects of obesity on lung volumes. These 
discrepancies may arise from heterogeneity in the severity of 
obesity and/or fat distribution, the precision of its measure-
ment, or other confounding factors, such as underlying lung 
disease or sex differences. These uncertainties may well be 
exaggerated when the respiratory effects of obesity are studied 
alongside another heterogeneous disease such as COPD. As 
such, caution is recommended in drawing conclusions.
Total respiratory system compliance is usually reduced in 
obese patients. Obesity alone appears to have a “deflationary” 
effect. Obese patients consistently have a reduced expiratory 
reserve volume (or FRC) proportional to the magnitude of 
obesity.99,108,110,113–120 Total lung capacity is usually not affected 
(ie, it remains within the lower limits of normal values), 
although some studies report decreases in cases of very 
severe obesity (body mass index .45 kg/m2).110,112,121 Obesity 
is associated with a small decrease in FEV
1
 and forced vital 
capacity (although they remain within normal values)108,122,123 
and the FEV
1
/forced vital capacity ratio is preserved.124 The 
physiological consequences of a combination of obesity and 
COPD are not well known and could theoretically provide 
advantages and disadvantages. On the one hand, both of these 
pathologies may have opposing effects in terms of lung vol-
umes, COPD being primarily hyperinflating and obesity being 
deflating. This could provide an advantage to patients with 
COPD who are obese by reducing the deleterious effects of 
dynamic hyperinflation. On the other hand, this combination 
could increase mechanical loading and airway closure,125 and 
thus worsen trapping of air in the lung.
While very few studies have addressed the impact of the 
combination of obesity and COPD on lung volumes, available 
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results suggest that compared with normal weight patients, 
obese patients with COPD have reduced TLC and FRC126–129 
and that lower lung volumes are maintained throughout exer-
cise.126,128,129 Obese patients with COPD still hyperinflate to a 
similar degree (Δ IC from rest to peak exercise capacity) than 
their normal weight counterparts.126,128,129  Obesity in COPD 
appears to have a deflating effect at rest, and as a consequence, 
even if patients hyperinflate at a similar rate, they remain at 
lower volumes during exercise.  Therefore, these studies all 
report that obese patients with COPD have either preserved or 
increased exercise capacity,126–129 except when walking is the 
testing modality.127 Mechanistic data126 showed that the elastic 
properties of the lung were better preserved and that diaphrag-
matic function appeared not to be better in obese patients 
with COPD. Also, the increased metabolic load induced by 
obesity appeared to be compensated by an increased ventila-
tory efficiency (ie, lower ventilatory equivalent for CO
2
) in 
these patients. The precise mechanisms by which obesity and 
COPD interact to affect lung volumes are presently not well 
known. They are likely influenced by several factors, such as 
COPD phenotype42 and fat distribution.96
Sex
Respiratory volumes and flows are significantly different 
between the sexes, as shown by the reference equations for 
lung function.130,131 These differences (mainly smaller lungs and 
maximal flow rates in women) may also affect dynamic volumes 
because fit women may suffer from expiratory flow limitation 
that induces an increase in EELV.132–134 It is therefore possible 
that COPD affects women differently than men. Women with 
COPD appear to be more susceptible to resting hyperinflation, 
despite lower tobacco use and younger age.135 When restricted to 
emphysema, women also present a different pattern of disease 
compared with men, ie, smaller airway lumen and thicker air-
way walls.136,137 During constant work rate cycle exercise testing 
at the same relative intensity, women with COPD hyperinflated 
at a rate similar to that in men (Δ IC).138 However, considering 
their smaller lung volumes, they reached a critical inspiratory 
reserve volume sooner than men and thus stopped exercise ear-
lier than men. Similar results were obtained in another sample 
of COPD patients.139 It would appear that women may be more 
susceptible to the deleterious effects of COPD because of their 
smaller respiratory systems compared with men.
Assessment of hyperinflation
Static assessments
In order to calculate lung hyperinflation at baseline, two 
subdivisions of the vital capacity must be measured. These 
are the IC and the expiratory reserve volume (Figure 1B).140 
Methods used for assessment of these parameters in COPD 
are body plethysmography, nitrogen washout, and helium 
dilution techniques.141 Body plethysmography is considered 
the gold standard. This test is performed in a body plethys-
mograph allowing measurement of intrathoracic gas while 
airflow is occluded. Based on Boyle’s law,142 changes in 
thoracic volumes caused by a compression or decompres-
sion of the gas in the lungs during respiratory maneuvers can 
be computed. FRC is thus obtained and constitutes the key 
measurement of static hyperinflation. A minimum of three 
values must be obtained, and the difference between the low-
est and the highest FRC must be within 5% to be considered 
reliable. The mean value is then reported. In elderly healthy 
subjects, residual volume and FRC represent 30% and 55% of 
TLC, respectively.130 In COPD, these values can be increased 
to 70% and 85% of the TLC for residual volume and FRC, 
respectively.143 Usually, lung volumes/capacities exceeding 
120%–130% of the predicted value are considered to be 
clinically relevant in COPD, but this remains arbitrary given 
that no consensus about the definition or severity of lung 
hyperinflation is available.131,141 It seems that the FRC cal-
culated by body plethysmography is overestimated because 
it includes both ventilated and nonventilated lung compart-
ments.130,142 In contrast, nitrogen washout and helium dilution 
techniques underestimate FRC in the presence of severe air-
flow obstruction or emphysema.32,140 Complete details about 
these three techniques are available in the latest American 
Thoracic Society/European Respiratory Society task force 
document.141 Finally, because of a lack of standardization, 
radiographic techniques144–147 are not commonly used clini-
cally to measure static hyperinflation in COPD.32 In fact, lung 
volumes calculated from radiographic techniques are based 
on the volume of gas within the outline of the thoracic cage 
and thus include the volume of tissue as well as the lung gas 
volume.140 This method is usually reserved for patients with 
a limited ability to correctly perform the other techniques. 
Nevertheless, high-resolution computed tomography might 
constitute a useful upcoming technique to assess hyperinfla-
tion in COPD.32
Dynamic assessments
Dynamic hyperinflation is determined from assessment of 
EELV (Figure 1B). This volume can be used interchangeably 
with FRC, although it is usually more appropriate to use it 
during exercise because this value is temporarily increased. 
EELV is commonly measured during exercise or any condi-
tion increasing minute ventilation by assessment of serial 
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IC measurements as recently described by Guenette et al.41 
As for the resting EELV, a minimum of three IC maneuvers 
must be performed at rest. Values within 10% or 150 mL of 
the largest acceptable IC are usually considered reproducible. 
During exercise, patients are asked to take a deep inspira-
tion after a normal expiration at specific intervals ranging 
from 1 to 3 minutes as well as at symptom limitation and 
during recovery. Because TLC remains stable during exer-
cise,148,149 a temporary decrease in IC reflects a temporary 
increase in EELV (Figure 1B and D). More than 80% of 
patients with moderate-to-severe COPD showed significant 
increases in EELV during exercise.11,13,46,150 This volume has 
been shown to be reliably measurable and is responsive to 
treatment in COPD.57,89 Moreover, inspiratory-to-total lung 
capacity ratio ,25% has also been used as a prognostic 
tool in COPD.151 A recent study showed that reduction of 
the inspiratory reserve volume (IC – V
T
 , Figure 1A and B) 
reflecting “room to breathe” was even more related to exercise 
dyspnea than EELV42 (Figure 1B). Finally, other methods 
such as optoelectronic plethysmography152 and respiratory 
inductance plethysmography153 are available for the assess-
ment of dynamic hyperinflation, but they are still mainly used 
for research purposes in COPD.
Management and treatment  
of hyperinflation
Bronchodilator therapy
Pharmacological interventions that reduce operating lung 
volumes and delay the onset of ventilatory limitation 
consistently reduce the intensity of dyspnea during exercise 
in patients with COPD.46,55,56 It should be noted, however, that 
the rates of increase in EELV (dynamic hyperinflation) and 
dyspnea symptoms during exercise are not modified after 
administration of bronchodilators. Rather, pharmacotherapy 
delays the development of restrictive ventilatory mechanics 
during exercise by deflating the lungs and decreasing EELV 
at rest. The resulting increase in resting IC causes a parallel 
downward shift in operating lung volumes during exercise 
in comparison with exercise performed without bronchodila-
tion (Figure 3).41,150 Thus, for any given exercise intensity or 
ventilation, patients breathe on the more linear portion of the 
respiratory system pressure–volume curve, with attendant 
improvements in neuromechanical coupling and, by exten-
sion, dyspnea. However, the absolute magnitude of dynamic 
hyperinflation does not change, and may even increase during 
peak exercise, reflecting the higher levels of ventilation that 
can be achieved following pharmacotherapy.10,45,90
Nonpharmacological interventions
ventilatory support
The use of noninvasive ventilatory support consistently 
increases endurance time and reduces perception of dys-
pnea during constant load cycling tasks in patients with 
COPD.154,155 However, assisting ventilation by continuous 
positive airway pressure or pressure support will not affect 
EELV at rest or the increase in EELV during exercise.156 
The use of ventilatory support techniques will therefore not 
directly impact either static or dynamic lung hyperinflation. 
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Figure 3 Acute effects of bronchodilation therapy on operational volume during constant work rate cycle ergometry in patients with COPD. 
Notes: example of operating lung volumes during constant work rate cycle ergometry performed at 75% maximal workload after dosing of placebo (gray symbols) or 
bronchodilation therapy (black symbols). Adapted with permission from the American College of Chest Physicians. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in 
symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168–1178.150
Abbreviations: COPD, chronic obstructive pulmonary disease; eeLv, end-expiratory lung volume; IC, inspiratory capacity; IRv, inspiratory reserve volume; TLC, total lung 
capacity; vT, tidal volume. 
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The effects of these interventions on dyspnea are probably 
mostly related to unloading of the inspiratory muscles dur-
ing exercise.155,157–160 Respiratory muscle function is often 
impaired in patients with COPD.161 As previously described, 
these muscles have to overcome higher elastic and threshold 
loads during exercise which increases the work and oxygen 
cost of breathing in comparison with healthy subjects.26,162 
Optimal continuous positive airway pressure reduces the elas-
tic work of breathing throughout inspiration, counterbalances 
intrinsic positive end expiratory pressure, and takes away 
the threshold load on the inspiratory muscles while pressure 
support provides variable resistive and elastic unloading of 
the ventilatory muscles.156,163
Unloading respiratory muscles by proportional assisted 
ventilation improved leg blood flow and exercise perfor-
mance during sustained high intensity exercise in healthy 
trained cyclists, indicating a competition for blood flow 
between respiratory and limb muscles.164,165 One study has so 
far investigated these mechanisms in patients with moderate-
to-severe COPD.166 These authors found positive effects of 
respiratory muscle unloading by proportional assisted ven-
tilation during a relatively short (average of 4–5 minutes) 
constant load cycling task on endurance time, leg muscle 
oxygenation, and dyspnea and leg fatigue symptoms.166
Oxygen/heliox administration
Supplemental oxygen during exercise consistently improves 
endurance and maximal exercise capacity and reduces 
ventilation and dyspnea at isotime during endurance exer-
cise testing in COPD patients with and without resting 
 hypoxemia.167 Oxygen supplementation during exercise 
delays the attainment of ventilatory limitation and accom-
panying intolerable symptoms of dyspnea during exercise by 
reducing ventilatory demand.168,169 Oxygen supplementation 
will however not affect EELV and IC at rest and will also 
not change EELV for a given level of ventilation during 
exercise.168,170 The improvements observed at a given level 
of exertion are therefore not caused by a direct effect on 
static or dynamic  hyperinflation. Both improved oxygen 
delivery to the peripheral muscles (resulting in less reli-
ance on anaerobic metabolism), and attenuated peripheral 
chemoreceptor stimulation have been proposed as possible 
explanations for the reduction in ventilatory demand for a 
given level of exertion.168,169
Heliox is a low density gas mixture (79% helium, 21% 
oxygen) that has been used in patients with COPD to reduce 
airflow resistance with increasing ventilatory requirements 
during exercise.171 Heliox supplementation has been shown 
to improve exercise intensity and endurance in patients with 
COPD in comparison with room air breathing.172 Effects on 
dyspnea are likely but less clearly documented in the cur-
rent literature.172 Two papers evaluating dyspnea at isotime 
during an endurance cycling task however consistently 
showed significant reductions in perception of dyspnea.171,173 
Heliox breathing increases the size of the maximal resting 
flow–volume envelope and seems to actually slow down the 
increase in EELV during exercise by decreasing airflow resis-
tance, thereby directly altering dynamic hyperinflation.170,171 
The response with regard to exercise capacity seems to be 
correlated with the magnitude of change in EELV during 
exercise.171 In three studies, the responses to hyperoxic 
helium (60%–70% helium, 30%–40% oxygen) and oxygen 
supplementation alone were compared during a constant load 
cycling task in patients with moderate (nonhypoxemic),173 
severe,174 and very severe (on long-term oxygen therapy) 
symptoms.175 These studies all found significant differences in 
endurance time in favor of the hyperoxic helium group.173–175 
They further demonstrated reductions in the resistive work 
of breathing,173 and reductions in exercise-induced dynamic 
hyperinflation (increases in EELV)174,175 in comparison with 
hyperoxia alone.
Lung volume reduction surgery
In selected patients, lung volume reduction surgery 
decreases static and dynamic hyperinflation, and improves 
neuromechanical coupling, respiratory muscle function, 
exertional dyspnea, and exercise performance.176–179 Lung 
volume reduction surgery increases maximal ventilatory 
capacity as evidenced by increases in both maximal vol-
untary ventilation and maximal minute ventilation at peak 
exercise.176–178,180–182 The positive effects of this interven-
tion on airflow obstruction have been ascribed to increases 
in lung elastic recoil or to reductions in TLC and residual 
volume leading to an increased vital capacity and improve-
ments in respiratory muscle function.183,184 However, the 
understanding of the exact mechanisms of improvement in 
lung function remains incomplete and needs to be improved 
to select the optimal patients for this procedure.183,184 Besides 
the effects on static hyperinflation, it seems that the inter-
vention also exerts a direct effect on dynamic hyperinfla-
tion during exercise.176–178 While minute ventilation has 
been reported to be stable at comparable work rates after 
lung volume reduction surgery, decreases in EELV have 
been observed, with reductions in breathing frequency and 
increases in V
T
.183 Thus, lung volume reduction surgery 
improves airway conductance and lung emptying both at 
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rest (comparable with bronchodilators) and during exercise 
(comparable with heliox breathing).
exercise
The improvements in dyspnea and exercise capacity during 
constant load cycling tasks after properly conducted exercise 
training programs are larger than those observed with any of 
the previously described interventions.185,186 Several physio-
logical and psychological factors, including a reduction in 
dynamic hyperinflation, have been proposed to explain these 
improvements.187–189 It is generally accepted that exercise 
training, unlike bronchodilators, does not have an impact 
on resting pulmonary mechanics.190 From the available data, 
it also appears that, unlike heliox breathing or lung volume 
reduction surgery, exercise training does not have a direct 
effect on the rate of increase in EELV (dynamic hyperinfla-
tion) during exercise.170 Similar to the acute effects of oxy-
gen supplementation, exercise training reduces ventilatory 
needs for a given level of exertion.170,190,191 This decrease in 
ventilatory needs is probably related to improvements in limb 
muscle function after training with an accompanying reduced 
reliance on anaerobic metabolism during exercise.187,189 Less 
ventilation will allow patients to reduce their respiratory 
rate, increase V
T
, and reduce EELV for a given workload 
and will eventually result in reduced symptoms of dyspnea 
and improved exercise endurance.187,189 For a given level of 
ventilation, EELV seems, however, not to be altered after 
exercise training.187–189
Breathing techniques
Pursed lip breathing is used spontaneously by some 
patients with severe dyspnea, airflow obstruction, and lung 
hyperinflation.192 Therapeutically, it has been applied to 
reduce breathing frequency and increasing V
T
 during exercise 
in several small studies, with mixed results in terms of dys-
pnea reduction and improvements in exercise capacity.192–194 
Spahija et al192 observed that during constant work bicycle 
exercise, a reduction in dyspnea during  application of pursed 
lip breathing was related to changes in EELV and pressure 
generation of the inspiratory muscles. Even though the evi-
dence base is limited, pursed lip breathing might be used on 
a trial-and-error basis in individual patients. A recent study 
by Collins et al195 used a computerized ventilation feedback 
intervention aimed at slowing respiratory rate in combination 
with an exercise training program and showed reductions in 
respiratory rate, ventilation, and dynamic hyperinflation at 
isotime during a constant load cycling task. Feasibility of 
this approach on a larger scale needs to be addressed.
Inspiratory muscle training
Strengthening inspiratory muscles by specific training 
programs has been applied frequently in patients with 
COPD with the aim to alleviate dyspnea and improve 
exercise capacity. Reduced contractile muscle effort has 
been proposed as an important dyspnea relieving mecha-
nism in studies that used ventilatory support to unload 
these muscles during exercise.157–160 Inspiratory muscle 
training aims to increase the capacity of these muscles to 
allow them to function at a lower fraction of their maximal 
capacity during exercise. Strong evidence supports effects 
of inspiratory muscle training to improve inspiratory muscle 
function (strength and endurance) and to reduce dyspnea 
and improve exercise capacity when applied as a stand-
alone intervention.196 Positive effects of inspiratory muscle 
training on operational lung volumes and breathing patterns 
during exercise have so far only been demonstrated in a 
single study.197 More research into the mechanisms linking 
inspiratory muscle training to reduction of dyspnea during 
daily activities is warranted.
Summary
Although measurement of FEV
1
 is mandatory to establish a 
diagnosis of COPD, research in recent years has clearly dem-
onstrated that hyperinflation, at rest and/or during exercise, 
is more closely associated with important clinical outcomes 
such as dyspnea and exercise intolerance than with expira-
tory flow indices. Hyperinflation has become an important 
endpoint in several clinical trials evaluating the efficacy 
of pharmacological and nonpharmacological therapeutic 
approaches to COPD. These trials have shown that measuring 
hyperinflation at rest and/or during exercise in the context of 
a multicenter randomized trial is feasible and valid. These 
trials have also confirmed that reducing hyperinflation in 
patients with COPD is a realistic therapeutic objective and 
is associated with relevant clinical benefits.
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